BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Truist Financial

Equities research analysts at Truist Financial assumed coverage on shares of BioNTech (NASDAQ:BNTX - Get Free Report) in a research note issued to investors on Friday, MarketBeat reports. The firm set a "buy" rating and a $172.00 price target on the stock. Truist Financial's price objective suggests a potential upside of 40.01% from the stock's current price.

A number of other equities research analysts also recently weighed in on BNTX. HSBC raised their price objective on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, October 7th. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. TD Cowen decreased their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. Finally, Jefferies Financial Group raised BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $142.72.

BioNTech Stock Up 0.6 %

NASDAQ BNTX traded up $0.70 during trading on Friday, reaching $122.85. 572,910 shares of the company's stock traded hands, compared to its average volume of 819,785. The company's 50 day simple moving average is $114.07 and its two-hundred day simple moving average is $103.06. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market cap of $29.45 billion, a price-to-earnings ratio of -58.50 and a beta of 0.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 earnings per share. As a group, sell-side analysts forecast that BioNTech will post -3.72 EPS for the current fiscal year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after purchasing an additional 111 shares during the last quarter. Blue Trust Inc. raised its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company's stock valued at $612,000 after buying an additional 435 shares during the period. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioNTech by 17.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock worth $465,000 after buying an additional 582 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.